Research

Advancing precision delivery of therapeutics

Our collaborating clinicians have extensive experience of using Renishaw’s technologies for the image-guided placement of Deep Brain Stimulation electrodes, as well many other therapies including drug and stem cell delivery.

Combining this experience with our growing range of stereotactic devices provides the perfect platform for the precise and rapid delivery of next generation therapeutics in to the Central Nervous System (CNS).

Renishaw is currently working with leading biotechnology and pharmaceutical companies to ensure that therapeutics that are showing great promise in the laboratory, have a means of delivery when clinical trials are performed.

The complexities of taking this step have historically led to therapy programmes with great potential failing to hit designated end-points. In several key cases these failures can at least be partly attributed to an inability to consistently, precisely deliver and contain the infusate in targeted volumes.

Renishaw is currently developing and testing a range of next-generation drug delivery devices that are demonstrating repeatability in infusion patterns, leading to consistency in observed therapy efficacy. In addition to offering to incorporate this development portfolio into therapeutic and academic research programmes, Renishaw offers a consultancy and associated design service to allow biotechnology and pharmaceutical companies to precisely specify delivery systems for optimal delivery of their therapeutics.

For more information please use the online enquiry form, e-mail neuro@renishaw.com or call +44 (0)1453 524900